Letter of response regarding adrenal SABR to the article published in the March 2024 journal publication: Prospective longitudinal assessment of quality of life after stereotactic ablative radiotherapy for oligometastases: Analysis of the population-based SABR-5 phase II trial by Cruz-Lim et al.
Irwin, A Clarke, H Ghafoor, Q Watkins, S
Irwin, A
Clarke, H
Ghafoor, Q
Watkins, S
Abstract
No abstract available.
MIDER Authors
Citations
Altmetric:
Date
2024-04-20
Type
Other
Subject
Oncology. Pathology.
Collections
Citation
Irwin A, Clarke H, Ghafoor Q, Watkins S. Letter of Response Regarding Adrenal SABR to the Article Published in the March 2024 Journal Publication: Prospective Longitudinal Assessment of Quality of Life after Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-based SABR-5 Phase II Trial by Cruz-Lim et al. Clin Oncol (R Coll Radiol). 2024 Jul;36(7):e239. doi: 10.1016/j.clon.2024.04.005. Epub 2024 Apr 20.
Journal / Source Title
Clinical Oncology
DOI
10.1016/j.clon.2024.04.005
PMID
38749807
Publisher
W.B. Saunders
Publisher’s URL
https://www.sciencedirect.com/science/journal/09366555